{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:55:06Z","timestamp":1781758506875,"version":"3.54.5"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Concepts of autoimmune disease have traditionally emphasized genetic susceptibility, antigen-specific immune activation, and inflammation as linear drivers of tissue injury and clinical symptoms. While this framework has been highly successful in explaining disease initiation and guiding the development of immunomodulatory therapies, accumulating evidence indicates important limitations in its capacity to account for long-term disease outcomes. In this review, we use multiple sclerosis (MS) as an illustrative case through which autoimmune theory can be critically examined. MS provides strong support for immune-mediated mechanisms in early disease, yet it also shows that neurodegeneration and disability accumulation often become uncoupled from overt inflammatory activity. These observations challenge linear models and sustained coupling between immune activity, tissue injury, and clinical progression. We use this gap between theoretical expectations and observed disease patterns to examine broader conceptual issues relevant to autoimmune and immune-mediated diseases, particularly the need to distinguish between mechanisms of susceptibility, inflammatory activity, and progressive worsening, and to incorporate temporal dynamics, interactions, and tissue-specific responses into explanatory models. We argue that the main contribution of MS lies not in serving as a generalizable model, but in clarifying the scope and limits of autoimmune theory and in underscoring the importance of theoretical refinement for organizing increasingly complex empirical evidence.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1849080","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:34:38Z","timestamp":1781757278000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Multiple sclerosis and the limits of classical autoimmune theory"],"prefix":"10.3389","volume":"17","author":[{"given":"Anna Karin","family":"Hedstr\u00f6m","sequence":"first","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institute","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Piehl","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institute","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-12-384929-8.00001-0","article-title":"Defining criteria for autoimmune disease","volume":"14","author":"Rose","year":"1993","journal-title":"Immunol Today"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1957.02980130015004","article-title":"Chronic thyroiditis and autoimmunization","volume":"164","author":"Witebsky","year":"1957","journal-title":"J Am Med Assoc"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/0952-7915(89)90192-1","article-title":"Cellular and genetic mechanisms of self-tolerance and autoimmunity","volume":"435","author":"Goodnow","year":"2005","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.19.1.163","article-title":"Anti-TFN alpha therapy of rheumatoid arthritis: what have we learned","volume":"19","author":"Feldmann","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nature01661","article-title":"Evolving concepts of rheumatoid arthritis","volume":"423","author":"Firestein","year":"2003","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1055\/s-0036-1579739","article-title":"Immunology of multiple sclerosis","volume":"23","author":"Sospedra","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-12-382227-7.00072-0","article-title":"Multiple sclerosis is an inflammatory T cell-mediated autoimmune disease","volume":"61","author":"Weiner","year":"2004","journal-title":"Arch Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(14)70305-9","article-title":"Role of the innate and adaptive immune responses in the course of multiple sclerosis","volume":"14","author":"Hemmer","year":"2015","journal-title":"Lancet Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028936","article-title":"Multiple sclerosis pathology","volume":"8","author":"Lassmann","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.68.801.507","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper typ 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J Exp Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1084\/jem.58.1.39","article-title":"Observations of attempts to produce acute disseminated encephalomyelitis in monkeys","volume":"58","author":"Rivers","year":"1993","journal-title":"J Exp Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1084\/jem.111.1.119","article-title":"Transfer of allergic encephalomyelitis in rats by means of lymph node cells","volume":"111","author":"Paterson","year":"1960","journal-title":"J Exp Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01302.x","article-title":"Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)","volume":"164","author":"Constantinescu","year":"2011","journal-title":"Br J Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-52001-2.00008-X","article-title":"The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment","volume":"122","author":"Robinson","year":"2014","journal-title":"Handb Clin Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awl075","article-title":"Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research","volume":"129","author":"Gold","year":"2006","journal-title":"Brain"},{"key":"B19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1084\/jem.192.3.393","article-title":"Clonal expansions of CD8+ T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction","volume":"192","author":"Babbe","year":"2000","journal-title":"J Exp Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1600-065x.2006.00441.x","article-title":"CNS immune privilege: hiding in plain sight","volume":"213","author":"Carson","year":"2006","journal-title":"Immunol Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2006.11.004","article-title":"What is immune privilege (not)","volume":"28","author":"Galea","year":"2007","journal-title":"Trends Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nature14432","article-title":"Structural and functional features of central nervous system lymphatic vessels","volume":"523","author":"Louveau","year":"2015","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20142290","article-title":"A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules","volume":"212","author":"Aspelund","year":"2015","journal-title":"J Exp Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nri3265","article-title":"The anatomical and cellular basis of immune surveillance in the central nervous system","volume":"12","author":"Ransohoff","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nri1130","article-title":"Three or more routes for leukocyte migration inito the central nervous system","volume":"3","author":"Ransohoff","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nature10251","article-title":"Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis","volume":"476","author":"Sawcer","year":"2011","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(14)70041-9","article-title":"Multiple sclerosis genetics","volume":"13","author":"Sawcer","year":"2014","journal-title":"Lancet Neurol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2395","article-title":"The genetics of multiple sclerosis: SNPs to pathways to pathogenesis","volume":"9","author":"Oksenberg","year":"2008","journal-title":"Nat Rev Genet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514564492","article-title":"Twin studies in multiple sclerosis: a meta-estimation of heritability and environmentality","volume":"21","author":"Fagnani","year":"2015","journal-title":"Mult Scler"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(72)90962-2","article-title":"HL-A antigens and multiple sclerosis","volume":"1","author":"Jersild","year":"1972","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav7188","article-title":"Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility","volume":"365","author":"Patsopoulos","year":"2019","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(22)00255-1","article-title":"Genetics of multiple sclerosis: lessons from polygenicity","volume":"21","author":"Goris","year":"2022","journal-title":"Lancet Neurol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.3.5777.725","article-title":"On the risk of multiple sclerosis according to age at immigration to South Africa","volume":"3","author":"Dean","year":"1971","journal-title":"Br Med J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/0301-0082(95)00033-x","article-title":"Migrant studies in multiple sclerosis","volume":"47","author":"Gale","year":"1995","journal-title":"Prog Neurobiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(85)92801-6","article-title":"Clinical viral infections and multiple sclerosis","volume":"1","author":"Sibley","year":"1985","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1172\/JCI14235","article-title":"Mechanisms for the induction of autoimmunity by infectious agents","volume":"108","author":"Wucherpfenning","year":"2001","journal-title":"J Clin Invest"},{"key":"B38","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-023-00775-5","article-title":"Epstein-Barr virus as a leading cause of multiple sclerosis: mechanisms and implications","volume":"19","author":"Bjornevik","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(22)00471-9","article-title":"Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy","volume":"22","author":"Aloisi","year":"2023","journal-title":"Lancet Neurol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41579-022-00770-5","article-title":"Epstein-Barr virus and multiple sclerosis","volume":"21","author":"Soldan","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212676","article-title":"Risk factors for multiple sclerosis in the context of Epstein-Barr virus infection","volume":"14","author":"Hedstr\u00f6m","year":"2023","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2004.tb00049.x","article-title":"Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis","volume":"14","author":"Serafini","year":"2004","journal-title":"Brain Pathol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22230","article-title":"A gradient of neuronal loss and meningeal inflammation in multiple sclerosis","volume":"68","author":"Magliozzi","year":"2010","journal-title":"Ann Neurol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.molmed.2019.11.003","article-title":"Epstein-Barr virus in multiple sclerosis: theory and emerging immunotherapies","volume":"26","author":"Bar-Or","year":"2020","journal-title":"Trends Mol Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2022.577935","article-title":"Mini-review of Epstein-Barr virus involvement in multiple sclerosis etiology and pathogenesis","volume":"371","author":"Aloisi","year":"2022","journal-title":"J Neuroimmunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20071030","article-title":"Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain","volume":"204","author":"Serafini","year":"2007","journal-title":"J Exp Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/nen.0b013e31827bfc62","article-title":"B-cell enrichment and Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis","volume":"72","author":"Magliozzi","year":"2013","journal-title":"J Neuropathol Exp Neurol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq371","article-title":"Smoking and two human leukocyte antigen genes interact to increase the risk of multiple sclerosis","volume":"134","author":"Hedstr\u00f6m","year":"2011","journal-title":"Brain"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0b013e3181c0d6e0","article-title":"Body size and risk of MS in two cohorts of US women","volume":"73","author":"Munger","year":"2009","journal-title":"Neurology"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105804","article-title":"The association between vitamin D deficiency and multiple sclerosis: an updated systematic review and meta-analysis","volume":"90","author":"Balasooriya","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09677-3","article-title":"Low sun exposure increases multiple sclerosis risk both directly and indirectly","volume":"267","author":"Hedstr\u00f6m","year":"2020","journal-title":"J Neurol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330848","article-title":"Influence of oral tobacco versus smoking on multiple sclerosis disease activity and progression","volume":"94","author":"Wu","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200334","article-title":"Obesity affects disease activity and progression, cognitive functioning, and quality of life in people with multiple sclerosis","volume":"12","author":"Wu","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16269","article-title":"Association between sun exposure habits and disease progression in multiple sclerosis","volume":"31","author":"Wu","year":"2024","journal-title":"Eur J Neurol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-325676","article-title":"DRB1-environment interactions in multiple sclerosis etiology: results from two Swedish case-control studies","volume":"92","author":"Hedstr\u00f6m","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-025-01212-1","article-title":"Impact of lifestyle factors post-infectious mononucleosis on multiple sclerosis risk","volume":"40","author":"Johansson","year":"2025","journal-title":"Eur J Epidemiol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199801293380502","article-title":"Axonal transection in the lesions of multiple sclerosis","volume":"338","author":"Trapp","year":"1998","journal-title":"N Engl J Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2012.168","article-title":"Progressive multiple sclerosis: pathology and pathogenesis","volume":"8","author":"Lassman","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awp070","article-title":"The relation between inflammation and neurodegeneration in multiple sclerosis brains","volume":"132","author":"Frischer","year":"2009","journal-title":"Brain"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann Neurol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/nejmoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac111","article-title":"Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study","volume":"145","author":"Portaccio","year":"2022","journal-title":"Brain"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.4655","article-title":"Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis","volume":"80","author":"Tur","year":"2023","journal-title":"JAMA Neurol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.0495","article-title":"Standardized definition of progression independent of relapse activity (PIRA) in relapsing-remitting multiple sclerosis","volume":"82","author":"M\u00fcller","year":"2025","journal-title":"JAMA Neurol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-023-00838-7","article-title":"Meningeal inflammation as a driver of cortical grey matter pathology and clinical progression in multiple sclerosis","volume":"19","author":"Magliozzi","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27034","article-title":"Smouldering-associated worsening in multiple sclerosis: an international consensus statement on definition, biology, clinical implications, and future directions","volume":"96","author":"Scalfari","year":"2024","journal-title":"Ann Neurol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26030884","article-title":"A window into new insights on progression independent of relapse activity in multiple sclerosis: role of therapies and current perspective","volume":"26","author":"Guerra","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103264","article-title":"Acting centrally or peripherally: a renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis","volume":"56","author":"Correale","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"B74","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/s1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1146\/annurev.immunol.8.1.579","article-title":"The T lymphocyte in experimental allergic encephalomyelitis","volume":"8","author":"Zamvil","year":"1990","journal-title":"Annu Rev Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders - towards clinical application","volume":"20","author":"Khalil","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518819380","article-title":"Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity","volume":"26","author":"H\u00f6gel","year":"2020","journal-title":"Mult Scler"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"12","author":"Hauser","year":"2020","journal-title":"Am J Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2415988","article-title":"Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis","volume":"392","author":"Fox","year":"2025","journal-title":"N Engl J Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2415985","article-title":"Tolebrutinib versus teriflunomide in relapsing multiple sclerosis","volume":"392","author":"Oh","year":"2025","journal-title":"N Engl J Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-443-23947-2.00081-3","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1263-7","article-title":"Distinct fibroblast subsets drive inflammation and damage in arthritis","volume":"570","author":"Croft","year":"2019","journal-title":"Nature"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-024-01014-1","article-title":"NMOSD and MOGAD: an evolving disease spectrum","volume":"20","author":"Uzawa","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s41232-023-00291-5","article-title":"Autoimmune-mediated astrocytopathy","volume":"43","author":"Kinoshita","year":"2023","journal-title":"Inflammation Regener"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-0314-x","article-title":"MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice","volume":"16","author":"Sastre-Garriga","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41746-023-00940-6","article-title":"A real-world clinical validation for AI-based MRI monitoring in multiple sclerosis","volume":"6","author":"Barnett","year":"2023","journal-title":"NPJ Dig Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1849080\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:34:42Z","timestamp":1781757282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1849080\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":88,"alternative-id":["10.3389\/fimmu.2026.1849080"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1849080","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"article-number":"1849080"}}